⚠ For research purposes only — not for human consumption. Not evaluated by the FDA.
Retatrutide
20mg
Retatrutide is a triple receptor agonist (GLP-1/GIP/glucagon) studied in preclinical and clinical metabolic research models for effects on metabolic pathways and body composition.
Preclinical Research Areas
- ●Studied in metabolic pathway research
- ●Investigated in preclinical body composition models
- ●GLP-1/GIP/glucagon receptor mechanism studies
- ●Published Phase 2 and Phase 3 clinical research data
Published research protocols examine incremental dosing over 4–24 week study periods. Refer to published literature for full study methodology and protocol design. This information is for research reference only — not for human use.
⚠ This information is from published scientific literature and is provided strictly for research reference. Not for human use. Follow all applicable laws and institutional protocols.
Multiple Phase 2 and Phase 3 trials published. One of the most studied GLP-1 triple agonists to date.
- Every order includes a Certificate of Analysis (CoA) from a third-party lab
- Ships within 1–2 business days from Wichita, KS
- Domestic US shipping only
- Discreet packaging, no product names on external labels
- Questions? Email optilifewellness@polsia.app
Research Community Reviews
"Excellent purity. COA matched expectations. Will reorder."
Marcus T.Need reconstitution water?
Bacteriostatic water is required to reconstitute lyophilized peptides for research applications.
